Last viewed: NVS

Prices are updated after-hours

NVS Nyse 2020 - 10 - 27

Novartis AG

NVS | News | $98.1 0.84% 1.3M

|

Health Technology

(0.0% 1d) (3.3% 1m) (-5.0% 1y) (0.0% 2d) (4.3% 3d) (4.8% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 214,832,181,756
http://www.novartis.com
Sec Filling | Patents | 103914 employees

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

add to watch list Paper trade email alert is off

Press-releases

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 0.0% | O: -0.49% H: 0.0% C: 0.0%
malaria positive treatment for novartis

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
Published: 2024-04-23 (Crawled : 18:00) - globenewswire.com
NVSEF | News | $96.0 52K

|

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
lutathera fda first approved tumors for novartis therapy

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Published: 2024-04-23 (Crawled : 05:00) - globenewswire.com
NVSEF | News | $96.0 52K

|

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
MOR | News | $18.03 -0.06% 110K

|

Health Technology

| 0.39% | O: 0.39% H: 0.0% C: 0.0%
sales expansion novartis growth

Over-The-Counter Drug Market size is set to grow by USD 58.54 billion from 2023-2027, Abbott Laboratories, Achelios Therapeutics Inc. and AstraZeneca Plc, and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-04-22 (Crawled : 22:00) - prnewswire.com
RBGPF | News | $52.06 4.8K

|

Consumer Non-Durables

| 0.08% | O: 0.98% H: 5.46% C: -0.89%
GLAXF | News | $19.54 2.6K

|

Health Technology

| -3.74% | O: -3.15% H: 0.0% C: -0.61%
AZNCF | News | $140.3 1.5K

|

Health Technology

| 1.13% | O: 0.96% H: 2.38% C: 0.17%
NVSEF | News | $96.0 52K

|

Health Technology

| 0.94% | O: 1.69% H: 0.02% C: -0.74%
RBGLY | News | $10.59 850K

|

| 1.7% | O: -0.28% H: 2.18% C: 1.99%
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.32% | O: 4.32% H: 0.0% C: 0.0%
GSK | News | $40.905 -0.81% 890K

|

Health Technology

| 1.6% | O: 0.17% H: 1.48% C: 1.43%
ABT | News | $106.96 -0.59% 2.6M

|

Health Technology

| 0.49% | O: 0.56% H: 0.41% C: -0.07%
SNY | News | $46.765 -1.94% 950K

|

Health Technology

| 1.7% | O: 1.7% H: 0.0% C: 0.0%
AZN | News | $71.26 0.58% 3.8M

|

Health Technology

| 1.03% | O: 0.4% H: 0.0% C: 0.0%
drug astrazeneca set key therapeutics market

Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17 (Crawled : 10:00) - prnewswire.com
TMO | News | $576.13 0.27% 1.1M

|

Health Technology

| 1.46% | O: -0.26% H: 0.03% C: -1.55%
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 6.51% | O: 0.87% H: 0.16% C: -0.59%
RGNX | $16.06 1.01% 170K

|

Health Technology

| -10.9% | O: -1.43% H: 2.27% C: -3.18%
global dna market

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 6.51% | O: 0.87% H: 0.16% C: -0.59%
kesimpta sclerosis novartis show benefits

Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | News A | $11.42 0.53% 1.7M

|

Health Technology

| 0.35% | O: -0.53% H: 0.0% C: -1.24%
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
PHG | News | $20.92 -0.43% 350K

|

Health Technology

| 1.64% | O: -1.21% H: 0.0% C: 0.0%
GSK | News | $40.905 -0.81% 890K

|

Health Technology

| 1.83% | O: -1.19% H: 0.52% C: -0.17%
VRNA | $15.59 130K

|

Health Technology

| -1.33% | O: 1.65% H: 2.43% C: 0.87%
reach treatment research market

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
REGN | News | $909.39 0.23% 210K

|

Health Technology

| -0.84% | O: -1.94% H: 0.43% C: -0.34%
OCUL | News | $4.68 -6.4% 2.1M

|

Health Technology

| -35.4% | O: -1.03% H: 3.66% C: 1.7%
ocular key leaders

Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $94.25 480

|

Health Technology

| 1.38% | O: -1.75% H: 0.85% C: 0.85%
AZNCF | News | $140.3 1.5K

|

Health Technology

| 3.21% | O: 2.1% H: 0.0% C: -2.52%
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
GSK | News | $40.905 -0.81% 890K

|

Health Technology

| 1.83% | O: -1.19% H: 0.52% C: -0.17%
BAX | $40.84 -0.44% 840K

|

Health Technology

| 2.45% | O: -0.1% H: 0.13% C: -1.08%
ABBV | News | $168.21 -0.78% 1.2M

|

Health Technology

| 4.87% | O: 0.32% H: 0.96% C: 0.22%
SNY | News | $46.765 -1.94% 950K

|

Health Technology

| 0.41% | O: -2.13% H: 0.0% C: 0.0%
BMRN | $91.405 -0.71% 700K

|

Health Technology

| 0.6% | O: -0.72% H: 0.0% C: 0.0%
AZN | News | $71.26 0.58% 3.8M

|

Health Technology

| 3.08% | O: -0.64% H: 0.45% C: -0.04%
AMGN | News | $274.15 0.22% 900K

|

Health Technology

| 3.02% | O: 0.41% H: 0.0% C: 0.0%
set therapeutics market

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | News | $98.1 0.84% 1.3M

|

Health Technology

| 4.95% | O: -1.46% H: 0.0% C: 0.0%
fabhalta nephropathy for novartis show

See all

Last 15 days Sec forms

File Id

Form

Published Date

Transaction Date

Direction

Code

Amount Transacted

Owned Amount

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

59%

41%

Top 10 Gainers

CZOO | $10.52 110.82% 10M

|

CSSE 4 | $0.3181 108.86% 170M

|

Consumer Services

BOF | $1.87 59.83% 100M

|

AMST | $3.1 55.0% 66M

|

Technology Services

LICN | $0.85 51.79% 13M

|

WIMI | $1.03 41.99% 15M

|

Technology Services

SKIL 4 | $8.045 40.89% 230K

|

MULN | News | $3.805 39.38% 11M

|

RILY | $30.01 38.17% 11M

|

MTC | $3.04 35.71% 6.7M

|

Technology Services

Last 48 Hours Insiders Buying

NWFL | News | $24.0 -0.46% 4.9K

|

| 17:00
MNSB P 310 | $15.82 -3.3% 21K

|

| 15:30
TPL P 3 | $584.82 -0.51% 20K

|

| 15:01
ISBA P 966 | $18.0001 3.1K

|

Finance and Insurance

| 15:01
MEGI | $12.05 0.58% 120K

|

| 00:30
CTRN P 29000 | $21.855 -1.69% 26K

|

| 22:00
CONN | $3.735 0.95% 23K

|

| 21:30
TGEN P 6000 | $0.685 6.6K

|

| 18:30
CMTV P 700 | $16.59 1K

|

Finance and Insurance

| 18:30
FNB | $13.625 -0.04% 700K

|

| 17:30
RMCF | $3.54 7K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar